Glaucoma effects around 70 million people worldwide and can cause irreversible loss of vision if not treated-but around half ...

Glaucoma stands as a preventable purveyor of blindness, particularly among Black and Hispanic communities. Genetic predispositions, socioeconomic disparities, and systemic barriers make glaucoma's ...

Recently published study aimed to determine the optimal end-tidal sevoflurane concentration for safely measuring intraocular pressure (IOP) in pediatric patients aged 1–12 months and 12–36 ...

If hypertension and diabetes and associated eye diseases are not treated on time then it may cause permanent vision loss ...

Microscopic in size, the company’s products Aliso Viejo-based Glaukos, dubbed the iStent, are often used in conjunction with ...

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy.

More information: Yu Cheng et al, Displacement-pressure biparametrically regulated softness sensory system for intraocular pressure monitoring, National Science Review (2024). DOI: 10.1093/nsr/nwae050 ...

Discover the groundbreaking patent by EyePoint Pharmaceuticals Inc for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists.

Significant DRSS improvement with no worsening observed. Positive Phase 2 data for Paxtrava also disclosed, showing substantial reduction in intraocular pressure.

Discover the groundbreaking patent by EyePoint Pharmaceuticals for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. Treat diabetic ...